Aldeyra Therapeutics, Inc. (ALDX) Earnings
Aldeyra Therapeutics, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.11. ALDX has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +33.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.13 | $-0.06 | +53.8% | — | — |
| Nov 5, 2025 | $-0.17 | $-0.13 | +23.5% | — | — |
| Aug 7, 2025 | $-0.21 | $-0.16 | +23.8% | — | — |
| May 14, 2025 | $-0.25 | $-0.17 | +32.0% | — | — |
| Feb 28, 2025 | $-0.25 | $-0.27 | -8.0% | $244526 | — |
| Nov 7, 2024 | $-0.25 | $-0.25 | +0.0% | — | — |
| Aug 1, 2024 | $-0.14 | $-0.28 | -100.0% | — | — |
| May 2, 2024 | $-0.08 | $-0.14 | -75.0% | — | — |
| Mar 7, 2024 | $-0.21 | $-0.08 | +61.9% | $392620 | -86.9% |
| Nov 3, 2023 | $-0.24 | $-0.14 | +41.7% | — | — |
| Aug 3, 2023 | $-0.31 | $-0.15 | +51.6% | — | — |
| May 4, 2023 | $-0.30 | $-0.27 | +10.0% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2022 · March 9, 2023
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Achieved two FDA accepted new drug applications: Reproxalap for dry eye disease and ADX-2191 (priority review for primary vitreoretinal lymphoma). • Focused on advancing next-generation RASP modulation platform: ADX-629, ADX-246, and ADX-248 in 2023. • ADX-629 in Phase 2 trials for indications like idiopathic nephrotic syndrome, Sjogren-Larsson syndrome, and atopic dermatitis; top-line results expected in second half of 2023. • Planned Phase 2 trial in moderate alcohol-associated hepatitis; top-line results expected for refractory/chronic cough trial in first half of 2023. • ADX-2191 NDA priority review for ocular lymphoma (PDUFA June 21, 2023); PDUFA for Reproxalap is November 23, 2023; ongoing partnering discussions for Reproxalap; Reproxalap showed superior visual acuity in dry eye safety trial. • Commercial preparations for Reproxalap and ADX-2191, with ADX-2191 targeting retinal surgeons and Reproxalap targeting optometrists.
Guidance
• Cash, cash equivalents, and marketable securities as of December 31, 2022 were $174.3 million, sufficient to fund operating expenses into the second half of 2024. • PDUFA dates: Reproxalap on November 23, 2023; ADX-2191 on June 21, 2023. • Top-line results expected for ADX-629 trials (Sjogren-Larsson syndrome, atopic dermatitis, idiopathic nephrotic syndrome), INVIGORATE-2 trial, and Phase 2 trial of ADX-2191 in retinitis pigmentosa in 2023.
Risks & headwinds
• Risks that clinical trial results may not predict future trial outcomes accurately. • Regulatory risks associated with FDA review and approval processes for NDAs. • Uncertainties in partnering discussions and commercialization of products like Reproxalap.
Analyst Q&A
Q: Marc Goodman asks about the side effect profile of oral products.
A: Todd Brady discusses RASP modulation's safety, noting ADX-629 has very few side effects and that RASP modulation avoids toxicity by influencing a family of mediators, not individual proteins.
Q: Yigal Nochomovitz inquires about Reproxalap partnering discussions and the AC trial.
A: Todd Brady mentions robust partnering conversations for Reproxalap, highlights Reproxalap's differentiators in dry eye, and discusses the AC trial's overlap with dry eye and potential impact on partnering decisions.
Q: Justin Kim asks about ADX-246 differentiation.
A: Todd Brady talks about ADX-246's potency and potential once-daily dosing, distinguishing it from ADX-629 which is administered twice daily.
Q: Sung asks about ADX-2191 priority review impact and visual acuity strategy.
A: Todd Brady explains regulatory strategy of submitting NDA for ocular lymphoma first, and discusses how visual acuity data from Reproxalap's safety trial will be highlighted in label negotiations.
Q: Catherine Novack asks about visual acuity change in Reproxalap's safety trial and RASP modulators in geographic atrophy.
A: Todd Brady notes Reproxalap's visual acuity improvement was statistically significant vs. vehicle, and discusses RASP modulation's dual mechanism in geographic atrophy (anti-inflammatory and preventing metabolite accumulation).
Q: Yale Jen asks about INVIGORATE-2 study status and retinitis pigmentosa data.
A: Todd Brady discusses INVIGORATE-2 enrollment nearing completion and the significance of retinitis pigmentosa trial as a milestone for ADX-2191